Sionna Completes Enrollment in SION-719 Phase 2a Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy SION?
"We entered 2026 with strong execution across our programs, highlighted by the recent completion of enrollment in our proof-of-concept Phase 2a trial of SION-719, an important milestone for Sionna," said Mike Cloonan, President and Chief Executive Officer of Sionna. "With both of our clinical stage NBD1 stabilizer programs on track for topline readouts this summer, we remain focused on advancing these first-in-class product candidates that could expand therapeutic options for people with CF."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SION?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SION
Wall Street analysts forecast SION stock price to rise
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 45.950
Low
24.00
Averages
47.80
High
60.00
Current: 45.950
Low
24.00
Averages
47.80
High
60.00
About SION
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sionna Therapeutics Director Indirectly Sells 55,345 Shares for $2.47 Million
- Transaction Overview: Peter A. Thompson, a director at Sionna Therapeutics, indirectly sold 55,345 shares between April 17 and 18, 2026, for approximately $2.47 million, indicating ongoing engagement with the company's stock.
- Holding Changes: This sale represented 2% of his indirect holdings, and while previous trades were larger, the decrease in trade size corresponds to reduced available shares after significant earlier dispositions, rather than a change in strategy.
- Market Performance Comparison: The weighted average sale price of around $44.67 was approximately 17.2% above the market price of $38.11 on April 25, 2026, reflecting a strong total return of 215% over the past year, providing robust context for the timing of the sale.
- Company Financial Position: Sionna Therapeutics currently holds about $310 million in cash, projected to sustain operations into 2028, which mitigates near-term dilution risks and offers management flexibility during key data readouts, showcasing its relatively strong position as a clinical-stage biotech firm.
See More
Sionna Therapeutics Executive Sells Shares
- Executive Share Sale: On March 5, 2026, Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick disposed of 10,250 shares of common stock via a derivative sale, totaling approximately $347,000, indicating her direct holdings have been reduced to zero, reflecting a complete turnover of her shares in the company.
- Transaction Structure Analysis: The transaction involved exercising options at $6.11 per share and immediately selling them at a weighted average price of about $33.86, indicating that this trade was executed under a pre-scheduled 10b5-1 plan adopted in June 2025, rather than being a reactive decision.
- Clinical Trial Progress: Sionna is currently running two clinical trials with topline data expected in mid-2026, including a Phase 2a trial of SION-719 and a Phase 1 dual combination trial of SION-451, with these results being critical for assessing the company's approach to normalizing CFTR function.
- Financial Overview: As of the end of 2025, Sionna had $310.3 million in cash, expected to fund operations into 2028, providing significant financial runway despite having no revenue yet, ensuring continued investment in clinical trials.
See More
Sionna Therapeutics Executive Sells Entire Shareholding
- Executive Share Sale: On March 5, 2026, Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick sold 10,250 shares for approximately $347,000, reducing her direct stock ownership to zero, which may indicate a lack of confidence in the company's future prospects.
- Options Exercise and Sale: Fitzpatrick exercised options at $6.11 per share and sold them at a weighted average price of about $33.86, locking in profits at a high price, although this move could raise questions about her long-term commitment to the company.
- Clinical Trial Progress: Sionna is currently conducting two clinical trials with topline data expected in mid-2026, which will be crucial for assessing the efficacy of its cystic fibrosis treatments, making these readouts critical for investor sentiment.
- Financial Status and Outlook: As of the end of 2025, Sionna had $310.3 million in cash, expected to fund operations into 2028, providing a significant runway for research and development despite currently having no revenue, which is essential for its future growth potential.
See More
Superstring Capital Management Acquires Stake in Sionna Therapeutics
- New Investment Highlight: Superstring Capital Management initiated a new position in Sionna Therapeutics by acquiring 180,593 shares in Q4 2025, with a position value of $7.43 million, indicating strong confidence in the biopharmaceutical company.
- Asset Management Proportion: This investment represents 3.98% of Superstring's reportable AUM as of December 31, 2025, showcasing its strategic positioning in the biopharmaceutical sector.
- Outstanding Stock Performance: As of February 13, 2026, Sionna Therapeutics shares were priced at $34.99, reflecting a remarkable 144% increase over the past year, significantly outperforming the S&P 500's 19% gain, highlighting market recognition of its future potential.
- Strong Financial Position: Sionna Therapeutics ended 2025 with approximately $310 million in cash, providing financial flexibility to support its development plans through 2028, even as R&D expenditures continue to rise.
See More
Superstring Capital Management Acquires Sionna Shares
- New Investment Position: Superstring Capital Management acquired 180,593 shares of Sionna Therapeutics in Q4, establishing a new position that now represents 3.98% of the fund's AUM, indicating ongoing interest in the biotech sector despite not being among the top five holdings.
- Value Appreciation: The position's value rose to $7.43 million by quarter-end, reflecting Superstring's confidence in Sionna's potential, particularly in its clinical-stage drug development, which could positively impact future returns.
- Strong Financial Position: Sionna Therapeutics has had a remarkable year, ending with approximately $310 million in cash, providing a runway into 2028 and allowing management greater flexibility in R&D spending while mitigating short-term dilution risks.
- Clinical Update Prospects: Sionna is expected to release multiple clinical updates in mid-year, particularly Phase 1 and Phase 2 data, which could rapidly shift market expectations regarding its valuation, drawing increased investor attention to its unique CFTR modulator development strategy.
See More
OrbiMed Advisors Reduces Stake in Sionna Therapeutics
- Share Reduction Details: On February 17, 2026, OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics, translating to an estimated $5.43 million trade, reducing its stake to 2.99% of its 13F reportable AUM.
- Quarter-End Position Value: Despite the reduction, the quarter-end position value for Sionna Therapeutics increased by $37.56 million, indicating a combination of trading activity and price appreciation, which suggests ongoing market confidence in the company.
- Financial Performance: As of 2026, Sionna Therapeutics shares were priced at $37.32, reflecting a remarkable 118% increase over the past year, significantly outperforming the S&P 500's 20% gain, highlighting its strong position in the biopharmaceutical sector.
- R&D Progress and Financial Health: Sionna ended 2025 with approximately $310 million in cash and equivalents, expected to fund operations through 2028, while ongoing clinical trials indicate promising product development potential.
See More
Sionna Therapeutics Director Indirectly Sells 55,345 Shares for $2.47 Million
- Transaction Overview: Peter A. Thompson, a director at Sionna Therapeutics, indirectly sold 55,345 shares between April 17 and 18, 2026, for approximately $2.47 million, indicating ongoing engagement with the company's stock.
- Holding Changes: This sale represented 2% of his indirect holdings, and while previous trades were larger, the decrease in trade size corresponds to reduced available shares after significant earlier dispositions, rather than a change in strategy.
- Market Performance Comparison: The weighted average sale price of around $44.67 was approximately 17.2% above the market price of $38.11 on April 25, 2026, reflecting a strong total return of 215% over the past year, providing robust context for the timing of the sale.
- Company Financial Position: Sionna Therapeutics currently holds about $310 million in cash, projected to sustain operations into 2028, which mitigates near-term dilution risks and offers management flexibility during key data readouts, showcasing its relatively strong position as a clinical-stage biotech firm.
See More
Sionna Therapeutics Executive Sells Shares
- Executive Share Sale: On March 5, 2026, Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick disposed of 10,250 shares of common stock via a derivative sale, totaling approximately $347,000, indicating her direct holdings have been reduced to zero, reflecting a complete turnover of her shares in the company.
- Transaction Structure Analysis: The transaction involved exercising options at $6.11 per share and immediately selling them at a weighted average price of about $33.86, indicating that this trade was executed under a pre-scheduled 10b5-1 plan adopted in June 2025, rather than being a reactive decision.
- Clinical Trial Progress: Sionna is currently running two clinical trials with topline data expected in mid-2026, including a Phase 2a trial of SION-719 and a Phase 1 dual combination trial of SION-451, with these results being critical for assessing the company's approach to normalizing CFTR function.
- Financial Overview: As of the end of 2025, Sionna had $310.3 million in cash, expected to fund operations into 2028, providing significant financial runway despite having no revenue yet, ensuring continued investment in clinical trials.
See More
Sionna Therapeutics Executive Sells Entire Shareholding
- Executive Share Sale: On March 5, 2026, Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick sold 10,250 shares for approximately $347,000, reducing her direct stock ownership to zero, which may indicate a lack of confidence in the company's future prospects.
- Options Exercise and Sale: Fitzpatrick exercised options at $6.11 per share and sold them at a weighted average price of about $33.86, locking in profits at a high price, although this move could raise questions about her long-term commitment to the company.
- Clinical Trial Progress: Sionna is currently conducting two clinical trials with topline data expected in mid-2026, which will be crucial for assessing the efficacy of its cystic fibrosis treatments, making these readouts critical for investor sentiment.
- Financial Status and Outlook: As of the end of 2025, Sionna had $310.3 million in cash, expected to fund operations into 2028, providing a significant runway for research and development despite currently having no revenue, which is essential for its future growth potential.
See More
Superstring Capital Management Acquires Stake in Sionna Therapeutics
- New Investment Highlight: Superstring Capital Management initiated a new position in Sionna Therapeutics by acquiring 180,593 shares in Q4 2025, with a position value of $7.43 million, indicating strong confidence in the biopharmaceutical company.
- Asset Management Proportion: This investment represents 3.98% of Superstring's reportable AUM as of December 31, 2025, showcasing its strategic positioning in the biopharmaceutical sector.
- Outstanding Stock Performance: As of February 13, 2026, Sionna Therapeutics shares were priced at $34.99, reflecting a remarkable 144% increase over the past year, significantly outperforming the S&P 500's 19% gain, highlighting market recognition of its future potential.
- Strong Financial Position: Sionna Therapeutics ended 2025 with approximately $310 million in cash, providing financial flexibility to support its development plans through 2028, even as R&D expenditures continue to rise.
See More
Superstring Capital Management Acquires Sionna Shares
- New Investment Position: Superstring Capital Management acquired 180,593 shares of Sionna Therapeutics in Q4, establishing a new position that now represents 3.98% of the fund's AUM, indicating ongoing interest in the biotech sector despite not being among the top five holdings.
- Value Appreciation: The position's value rose to $7.43 million by quarter-end, reflecting Superstring's confidence in Sionna's potential, particularly in its clinical-stage drug development, which could positively impact future returns.
- Strong Financial Position: Sionna Therapeutics has had a remarkable year, ending with approximately $310 million in cash, providing a runway into 2028 and allowing management greater flexibility in R&D spending while mitigating short-term dilution risks.
- Clinical Update Prospects: Sionna is expected to release multiple clinical updates in mid-year, particularly Phase 1 and Phase 2 data, which could rapidly shift market expectations regarding its valuation, drawing increased investor attention to its unique CFTR modulator development strategy.
See More
OrbiMed Advisors Reduces Stake in Sionna Therapeutics
- Share Reduction Details: On February 17, 2026, OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics, translating to an estimated $5.43 million trade, reducing its stake to 2.99% of its 13F reportable AUM.
- Quarter-End Position Value: Despite the reduction, the quarter-end position value for Sionna Therapeutics increased by $37.56 million, indicating a combination of trading activity and price appreciation, which suggests ongoing market confidence in the company.
- Financial Performance: As of 2026, Sionna Therapeutics shares were priced at $37.32, reflecting a remarkable 118% increase over the past year, significantly outperforming the S&P 500's 20% gain, highlighting its strong position in the biopharmaceutical sector.
- R&D Progress and Financial Health: Sionna ended 2025 with approximately $310 million in cash and equivalents, expected to fund operations through 2028, while ongoing clinical trials indicate promising product development potential.
See More
